Evidence map›Paper›PMID 42396522›Full record

ArticleResearch square2026

COVID-19 Vaccine Reactogenicity Marks an Innate Inflammatory Response Associated With HLA Variation and Enhanced Protection.

Anshika Srivastava, Demetra S M Chatzileontiadou, Anurag Adhikari, Rayo Suseno, Sean Lin, Juliano Boquett, Jamie Tuibeo, Tasneem Yusufali, Noah D Peyser, Ticiana D J Farias and 29 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Anshika SrivastavaDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.
Demetra S M ChatzileontiadouImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.ORCID 0000-0003-1132-8952
Anurag AdhikariImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.
Rayo SusenoDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.
Sean LinDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.
Juliano BoquettDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.
Jamie TuibeoImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.
Tasneem YusufaliDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.
Noah D PeyserDepartment of Medicine, University of California San Francisco, San Francisco, CA 94158, USA.
Ticiana D J FariasUniversity of Colorado Anschutz School of Medicine, Aurora, CO.
Katherine M KichulaUniversity of Colorado Anschutz School of Medicine, Aurora, CO.
Andrea T NguyenImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.
Irvin JoseImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.
Dhilshan JayasingheImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.
Samuel Liwei LeongImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.
Alexis BeattyDepartment of Medicine, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-8405-7386
Katerina TarassiImmunology-Histocompatibility Department, "Evangelismos" General Hospital, Athens, Greece.
Elissavet KontouImmunology-Histocompatibility Department, "Evangelismos" General Hospital, Athens, Greece.
Janesha C MaddumageImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.
Kleio AmpelakiotouImmunology-Histocompatibility Department, "Evangelismos" General Hospital, Athens, Greece.
Alexandra TsirogianniImmunology-Histocompatibility Department, "Evangelismos" General Hospital, Athens, Greece.
Michael J Dewar-OldisImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.
Tuong-Khanh My TuDepartment of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe University, Bundoora, VIC 3086, Australia.
Thanh Kha PhanDepartment of Biochemistry and Chemistry, School of Agriculture, Biomedicine and Environment, La Trobe University, Bundoora, VIC 3086, Australia.
Peter J BarnardImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.
Joseph J SabatinoDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-6804-7441
Dimitrios ZoulasBlood Bank Department, "Evangelismos" General Hospital, Athens, Greece.
Emily AriensBASE mRNA Facility, Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, Brisbane, QLD 4067, Australia.
Timothy R MercerBASE mRNA Facility, Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland, Brisbane, QLD 4067, Australia.
Emma J GrantImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.
Lloyd D'OrsognaSchool of Medicine, University of Western Australia, Nedlands 6009, Australia.
Corey SmithQueensland Immunology Research Centre and Inflammation and Infection Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.ORCID 0000-0002-7550-9595
Paul J NormanUniversity of Colorado Anschutz School of Medicine, Aurora, CO.
Gregory M MarcusDepartment of Medicine, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-5197-7696
Jeffrey E OlginDepartment of Medicine, University of California San Francisco, San Francisco, CA 94158, USA.
Mark J PletcherDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0002-6966-1312
Martin MaiersCIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN 55401-1206, USA.ORCID 0000-0002-0198-2064
Stephanie GrasImmunity and Infection Program, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, VIC 3086, Australia.ORCID 0000-0001-7416-038X
Jill A HollenbachDepartment of Neurology, University of California San Francisco, San Francisco, CA 94158, USA.ORCID 0000-0001-6572-7962

Funding

MHC Variation in Host Response to SARS-CoV2 and COVID-19 OutcomesR01AI159260 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOLLENBACH, JILL ALLISON · 2021 to 2025
$4.0M
The landscape of HLA mediated variation in health and immunityR01AI158861 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOLLENBACH, JILL ALLISON · 2021 to 2025
$3.5M
Natural Killer cells and the Immunogenetics of COVID-19R01AI158410 · NIAID · UNIVERSITY OF COLORADO DENVER · PI NORMAN, PAUL JOHN · 2021 to 2024
$2.9M
NIAID NIH HHS R01 AI158410NIAID NIH HHS R01 AI158861NIAID NIH HHS R01 AI159260
6 · The paper itself

Abstract

Vaccination against SARS-CoV-2 has been central to mitigating the COVID-19 pandemic, although transient systemic side effects remain common and contribute to vaccine hesitancy. While previous studies have implicated

Identifiers

PMID42396522
PMCPMC13321264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.